In fiscal 2026, which ended Dec 31, 2025, Anaptysbio, Inc. reported revenue of $234.6 million. It recorded a net loss of $13.2 million. Operating income came to $226.9 million, an operating margin of 96.7%. Diluted earnings per share were -$0.44. Over the twelve months ended Mar 31, 2026, revenue was $232.4 million and the net loss was $26.8 million. Across the 9 fiscal years shown, revenue grew from $10.0 million in fiscal 2017 to $234.6 million in fiscal 2026, about 48.4% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Mar 31, 2026
|
FY 2026
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
232
+107.7%
|
235
|
91
+432.0%
|
17
+66.8%
|
10
-83.7%
|
63
-15.8%
|
75
+837.5%
|
8
+60.0%
|
5
-50.0%
|
10
|
| Research and development |
—
|
—
|
—
|
—
|
89
-9.8%
|
98
+23.1%
|
80
-19.4%
|
99
+76.8%
|
56
+90.9%
|
29
|
| Selling, general and administrative |
23
+51.8%
|
11
|
14
-67.5%
|
42
+14.5%
|
37
+70.5%
|
21
+14.0%
|
19
+17.1%
|
16
+3.7%
|
16
+66.3%
|
9
|
| Operating income |
220
+172.0%
|
227
|
66
+140.2%
|
-164
-42.8%
|
-115
-102.7%
|
-57
-137.9%
|
-24
+77.8%
|
-107
-61.0%
|
-67
-131.8%
|
-29
|
| Other income (expense) |
-71
-57.9%
|
-65
|
-35
-4543.3%
|
1
+105.8%
|
-14
-1279.4%
|
-1
-124.9%
|
4
-60.3%
|
10
+104.0%
|
5
+478.1%
|
-1
|
| Pretax income |
149
|
162
|
31
+119.0%
|
-164
-27.1%
|
-129
-122.7%
|
-58
-190.0%
|
-20
+79.6%
|
-97
-57.6%
|
-62
-105.7%
|
-30
|
| Income tax |
1
|
1
|
0
+4050.0%
|
-0
-116.7%
|
0
|
0
|
0
+100.0%
|
-0
+20.8%
|
-0
|
0
|
| Net income |
-27
+81.0%
|
-13
|
-145
+11.2%
|
-164
-27.1%
|
-129
-122.7%
|
-58
-190.0%
|
-20
+79.5%
|
-97
-57.9%
|
-62
-105.0%
|
-30
|
| Basic EPS |
-0.95
+80.2%
|
-0.46
|
-5.12
+15.8%
|
-6.08
-33.0%
|
-4.57
-116.6%
|
-2.11
|
—
|
-3.60
-44.0%
|
-2.50
-64.5%
|
-1.52
|
| Diluted EPS |
-0.90
+80.5%
|
-0.44
|
-4.92
+19.1%
|
-6.08
-33.0%
|
-4.57
-116.6%
|
-2.11
|
—
|
-3.60
-44.0%
|
-2.50
-64.5%
|
-1.52
|
| Weighted average shares, basic |
28
-3.6%
|
29
|
28
+5.4%
|
27
-4.4%
|
28
+2.7%
|
27
|
—
|
—
|
—
|
—
|
| Weighted average shares, diluted |
30
-2.4%
|
30
|
30
+9.7%
|
27
-4.4%
|
28
+2.7%
|
27
|
—
|
—
|
—
|
—
|
| Other measures | ||||||||||
| Depreciation and amortization |
0
+33.3%
|
0
|
0
-96.9%
|
1
-3.4%
|
1
+9.0%
|
1
+10.7%
|
1
+8.8%
|
1
+63.2%
|
0
+72.1%
|
0
|
| EBITDA |
220
+172.0%
|
227
|
66
+140.4%
|
-164
-43.0%
|
-114
-103.7%
|
-56
-141.0%
|
-23
+78.2%
|
-107
-61.0%
|
-66
-132.2%
|
-29
|
| Interest coverage |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
-103.20x
|
-40.39x
|
-16.21x
|
| Margins | ||||||||||
| Operating margin |
94.58%
|
96.72%
|
72.47%
|
-958.27%
|
-1,119.41%
|
-89.93%
|
-31.84%
|
-1,342.90%
|
-1,334.44%
|
-287.81%
|
| Pretax margin |
63.99%
|
69.17%
|
34.11%
|
-953.68%
|
-1,251.09%
|
-91.49%
|
-26.57%
|
-1,218.60%
|
-1,236.96%
|
-300.70%
|
| Profit margin |
-11.53%
|
-5.64%
|
-159.10%
|
-953.66%
|
-1,251.33%
|
-91.49%
|
-26.57%
|
-1,216.70%
|
-1,233.12%
|
-300.70%
|
| EBITDA margin |
94.59%
|
96.73%
|
72.49%
|
-954.47%
|
-1,112.85%
|
-88.95%
|
-31.09%
|
-1,336.48%
|
-1,328.14%
|
-285.98%
|
| Effective tax rate |
0.52%
|
0.48%
|
0.51%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANAB (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1370053
- Former names
- ANAPTYSBIO INC (until Jun 12, 2019); ANAPTYS BIOSCIENCES INC (until Nov 20, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.